Turnstone raises $41.4 million series B round

Turnstone Biologics Inc. (Toronto, Ontario) raised $41.4 million in a series B round led by new investor OrbiMed. First-time investor F-Prime Capital Partners and existing investors FACIT and Versant Ventures also participated.

President and CEO Sammy Farah told BioCentury the money will enable Turnstone to complete four Phase I/II trials over the next three years...